Skip to content

The curative effect analysis of combined application of dexmedetomidine and remifentanil on neurosurgical intervention

The curative effect analysis of combined application of dexmedetomidine and remifentanil on neurosurgical intervention

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008494
Enrollment
Unknown
Registered
2016-05-19
Start date
2016-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

D group:dexmedetomidine and remifentanil

Sponsors

Liaocheng People’s Hospital, Liaocheng,Shandong province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 45 to 65 years; 2. American Society of Anesthesiologists physical status II-III; 3. Glasgow Coma Scale score>=13.

Exclusion criteria

Exclusion criteria: 1. A history of craniotomy; 2. Heart disease (heart rate<=50 bpm); 3. Severe hypertension (systolic blood pressure=180 mmHg or diastolic blood pressure=110 mmHg); 4. A history of lung disease (peripheral capillary oxygen saturation [SpO2] < 93% when breathing air in the awake state); 5. A history of liver or kidney dysfunction; 6. Hypersensitivity (allergic) or intolerance to dexmedetomidine or remifentanil; 7. Body weight beyond ± 15% of the standard body weight; 8. Suspected postoperative intracranial hemorrhage; 9. Study termination by the researchers from a medical perspective or the patients refusal to participate.

Design outcomes

Primary

MeasureTime frame
Vital signs;Vasoactive drugs;

Secondary

MeasureTime frame
the scores of pain;Ramsay score;ICU residence time;Adverse reactions;

Countries

China

Contacts

Public ContactChunguang Ren

Liaocheng People's Hospital, Liaocheng, Shandong

weiyichunguang@163.com+86 13561239696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026